Page 45 - Read Online

Kaneko et al. Hyperostosis of metastatic adenocarcinoma by gefitinib

should not be discontinued even if adverse effects of N, Kajiki A. Flare phenomenon following gefitinib treatment of
other organs might emerge. lung adenocarcinoma with bone metastasis. Tohoku J Exp Med
2012;228:163-8.
Authors’ contributions 4. Garfield D. Increasing osteoblastic lesions as a manifestation of a
major response to gefitinib. J Thorac Oncol 2006;1:859-60.
Patient’s treatment and manuscript’s preparation: H. 5. Lind JS, Postmus PE, Smit EF. Osteoblastic bone lesions developing
Kaneko during treatment with erlotinib indicate major response in patients
Data acquisition: M. Yoshida with non-small cell lung cancer: a brief report. J Thorac Oncol
Study design: K. Shimura, Y. Matsumoto 2010;5:554-7.
Manuscript’s review: M. Taniwaki, J. Kuroda 6. Yasuda Y, Kawamura K, Ichikado K, Yoshioka M. Alkaline
phosphatase flare phenomenon following epidermal growth factor-
Financial support and sponsorship tyrosine kinase inhibitor treatment of non-small cell lung cancer:
None. report of a case and case review. Respir Med Case Rep 2014;13:51-3.
7. Chao HS, Chang CP, Chiu CH, Chu LS, Chen YM, Tsai CM. Bone
Conflicts of interest scan flare phenomenon in non-small-cell lung cancer patients treated
with gefitinib. Clin Nucl Med 2009;34:346-9.
There are no conflicts of interest. 8. Shimazaki C, Uchida R, Nakano S, Namura K, Fuchida S, Okano A,
Okamoto M, Inaba T. High serum bone-specific alkaline phosphatase
Patient consent level after bortezomib-combined therapy in refractory multiple
All involved patients give their consent forms. myeloma: possible role of bortezomib on osteoblast differentiation.
Leukemia 2005;19:1102-3.
Ethics approval 9. Normanno N, De Luca A, Aldinucci D, Maiello MR, Mancino M,
Ethics approval was obtained from Institute Review D’Antonio A, De Fillippi R, Pinto A. Gefitinib inhibits the ability of
Board for case reports. human bone marrow stromal cells to induce osteoclast differentiation:
implications for the pathogenesis and treatment of bone metastasis.
Endocr Relat Cancer 2005;12:471-82.
REFERENCES 10. Pluquet E, Cadranel J, Legendre A, Beau Faller M, Souquet PJ,
Zalcman G, Perol M, Fraboulet G, Oliveiro G, De Fraipont F, Quoix
1. Coleman RE, Whitaker KB, Moss DW, Mashiter G, Fogelman I, E, Lantuejoul S, Milleron B, Moro-Sibilot D. Osteoblastic reaction in
Rubens RD. Biochemical prediction of response of bone metastases non-small cell lung carcinoma and its association to epidermal growth
to treatment. Br J Cancer 1988;58:205-10. factor receptor tyrosine kinase inhibitors response and prolonged
2. Arai Y, Kojima A. A case of lung cancer with alkaline phosphatase survival. J Thorac Oncol 2010;5:491-6.
flare phenomenon during gefitinib therapy. Nihon Kokyuki Gakkai 11. Yoshimoto A, Kasahara K, Kimura H, Kita T, Fujimura M, Nakao
Zasshi 2007;45:962-6. (in Japanese) S. Transient liver injury caused by gefitinib. Nihon Kokyuki Gakkai
3. Hashisako M, Wakamatsu K, Ikegami S, Kumazoe H, Nagata Zasshi 2004;42:56-61. (in Japanese)

Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ February 23, 2017 37